MBX Biosciences (MBX) Free Cash Flow (2023 - 2026)

MBX Biosciences has disclosed Free Cash Flow across 4 years of filings, most recently posting -$20.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$20.6 million, up 10.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$79.3 million (down 16.7% YoY), and the FY2025 annual result was -$81.9 million, down 47.38% from the prior year.
• Free Cash Flow came in at -$20.6 million for Q1 2026 at MBX Biosciences, down from -$19.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$10.7 million in Q1 2024 to a low of -$23.2 million in Q1 2025.
• The 4-year median for Free Cash Flow is -$17.3 million (2024), against an average of -$16.9 million.
• Across the five-year window, Free Cash Flow slumped 115.75% in 2025 and gained 10.94% in 2026, its largest moves.
• MBX Biosciences' Free Cash Flow stood at -$11.2 million in 2023, then sank by 51.33% to -$16.9 million in 2024, then dropped by 13.02% to -$19.1 million in 2025, then slipped by 8.12% to -$20.6 million in 2026.
• The last three Free Cash Flow figures came in at -$20.6 million (Q1 2026), -$19.1 million (Q4 2025), and -$21.9 million (Q3 2025), per Business Quant data.